Fig. 5

Administration of Y-27632 and U73122 abolished the effect of O-1602. a In the EPM test, co-administration of Y-27632 or U73122 with O-1602 decreased the time spent and the number of entries in the open arms. **p < 0.01 versus control group; ^# p < 0.05, ^## p < 0.01 versus vehicle group; ^& p < 0.05 versus O-1602-treated group. b In the OFT, co-administration of Y-27632 or U73122 with O-1602 decreased the time in the central area and the total distance traveled. *p < 0.05, **p < 0.01 versus control group; ^# p < 0.05 versus vehicle group; ^& p < 0.05 versus O-1602-treated group. c Administration of Y-27632 or U73122 reversed O-1602-induced expression of GluA1, GluN2A, and GluN2B. *p < 0.05, **p < 0.01 versus control group; ^## p < 0.01 versus vehicle group; ^& p < 0.05, ^&& p < 0.01 versus O-1602 group. d Administration of Y-27632 or U73122 had no effect on the phosphorylation of AKT at S473 and T308. e Administration of Y-27632 and U73122 decreased O-1602-induced expression of p-ERK. **p < 0.01 versus control group; ^## p < 0.01 versus vehicle group; ^& p < 0.05 versus O-1602 group. Each group contains 6–8 mice. Data are from three independent experiments